Global Iloprost Drugs

Iloprost Drugs Comprehensive Study by Type (OTC, Prescribed), Application (Pulmonary Arterial Hypertension (PAH), High Blood Pressure), Route of Administration (Intravenous, Respiratory (Inhalation)), Distribution Channel (Online, Hospital Pharmacies) Players and Region - Global Market Outlook to 2030

Iloprost Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Iloprost Drugs Market Scope?
Iloprost drug is a medication that is used to treat pulmonary arterial hypertension, scleroderma, Raynaud's phenomenon, and other diseases in which the blood vessels are constricted and blood cannot flow to the tissues. The medication is prescribed so that it increases the ability to exercise or to reduce the symptoms. The drug works by relaxing the blood vessels and hence reducing the tension. The drug is available in two types and is available either online or offline. It can be administered either by inhalation or by Intravenous. The Iloprost dilates the narrowed blood vessels (arteries) in the lungs which results in decreased pulmonary blood pressure to the heart.

Influencing Trend:
Rising Awareness about Mental Health and Huge Funding In R&D and Various Initiatives by Government

Market Growth Drivers:
Increasing Geriatric Population, Rapid Urbanization and Globalization Leading to Human Health Being Adversely Affected and Change In Lifestyle and Elevated Stress Levels

Challenges:
Availability of Alternative Therapies

Restraints:
Side Effects Caused by Iloprost Drugs and High Cost of Drugs

Opportunities:
Growing Improvements and Developments Across the Healthcare Industry

The Iloprost Drugs market study is being classified by Type (OTC and Prescribed), by Application and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Iloprost Drugs market throughout the predicted period.

GlaxoSmithKline plc (United Kingdom), Actelion Pharmaceuticals Ltd (Switzerland), United Therapeutics Corporation (United States), Pfizer Inc (United States), Gilead Sciences Inc (United States), Eli Lilly and Company (United States), Steady Med Ltd (United States), Teva Pharmaceuticals Inc (Israel), Bayer AG (Germany), Actelion Pharmaceuticals Ltd (Switzerland), Novartis International AG (Switzerland), Reata Pharmaceuticals Inc (United States) and Toray Industries Inc (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Liquidia Technologies Inc. (United States) and Nuventra Pharma Sciences (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Iloprost Drugs market by Type, Application and Region.

On the basis of geography, the market of Iloprost Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In October 2022 ,Pfizer Inc. announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD).
In September 2023, Pfizer Inc. and BioNTech SE announced that they received approval from the U.S. Food and Drug Administration (FDA) for their supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation).


Key Target Audience
Manufacturers of Iloprost Drugs, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Iloprost Drugs Market Study: Important Years
AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Iloprost Drugs Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Iloprost Drugs industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • OTC
  • Prescribed
By Application
  • Pulmonary Arterial Hypertension (PAH)
  • High Blood Pressure
By Route of Administration
  • Intravenous
  • Respiratory (Inhalation)

By Distribution Channel
  • Online
  • Hospital Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population
      • 3.2.2. Rapid Urbanization and Globalization Leading to Human Health Being Adversely Affected
      • 3.2.3. Change In Lifestyle and Elevated Stress Levels
    • 3.3. Market Challenges
      • 3.3.1. Availability of Alternative Therapies
    • 3.4. Market Trends
      • 3.4.1. Rising Awareness about Mental Health
      • 3.4.2. Huge Funding In R&D and Various Initiatives by Government
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Iloprost Drugs, by Type, Application, Route of Administration, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Iloprost Drugs (Value)
      • 5.2.1. Global Iloprost Drugs by: Type (Value)
        • 5.2.1.1. OTC
        • 5.2.1.2. Prescribed
      • 5.2.2. Global Iloprost Drugs by: Application (Value)
        • 5.2.2.1. Pulmonary Arterial Hypertension (PAH)
        • 5.2.2.2. High Blood Pressure
      • 5.2.3. Global Iloprost Drugs by: Route of Administration (Value)
        • 5.2.3.1. Intravenous
        • 5.2.3.2. Respiratory (Inhalation)
      • 5.2.4. Global Iloprost Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Hospital Pharmacies
      • 5.2.5. Global Iloprost Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Iloprost Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Actelion Pharmaceuticals Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. United Therapeutics Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gilead Sciences Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Steady Med Ltd (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceuticals Inc (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Actelion Pharmaceuticals Ltd (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis International AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Reata Pharmaceuticals Inc (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Toray Industries Inc (Japan)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Iloprost Drugs Sale, by Type, Application, Route of Administration, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Iloprost Drugs (Value)
      • 7.2.1. Global Iloprost Drugs by: Type (Value)
        • 7.2.1.1. OTC
        • 7.2.1.2. Prescribed
      • 7.2.2. Global Iloprost Drugs by: Application (Value)
        • 7.2.2.1. Pulmonary Arterial Hypertension (PAH)
        • 7.2.2.2. High Blood Pressure
      • 7.2.3. Global Iloprost Drugs by: Route of Administration (Value)
        • 7.2.3.1. Intravenous
        • 7.2.3.2. Respiratory (Inhalation)
      • 7.2.4. Global Iloprost Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Hospital Pharmacies
      • 7.2.5. Global Iloprost Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Iloprost Drugs: by Type(USD Million)
  • Table 2. Iloprost Drugs OTC , by Region USD Million (2018-2023)
  • Table 3. Iloprost Drugs Prescribed , by Region USD Million (2018-2023)
  • Table 4. Iloprost Drugs: by Application(USD Million)
  • Table 5. Iloprost Drugs Pulmonary Arterial Hypertension (PAH) , by Region USD Million (2018-2023)
  • Table 6. Iloprost Drugs High Blood Pressure , by Region USD Million (2018-2023)
  • Table 7. Iloprost Drugs: by Route of Administration(USD Million)
  • Table 8. Iloprost Drugs Intravenous , by Region USD Million (2018-2023)
  • Table 9. Iloprost Drugs Respiratory (Inhalation) , by Region USD Million (2018-2023)
  • Table 10. Iloprost Drugs: by Distribution Channel(USD Million)
  • Table 11. Iloprost Drugs Online , by Region USD Million (2018-2023)
  • Table 12. Iloprost Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 13. South America Iloprost Drugs, by Country USD Million (2018-2023)
  • Table 14. South America Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 15. South America Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 16. South America Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 17. South America Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 18. Brazil Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 19. Brazil Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 20. Brazil Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 21. Brazil Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 22. Argentina Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 23. Argentina Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 24. Argentina Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 25. Argentina Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 26. Rest of South America Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 29. Rest of South America Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 30. Asia Pacific Iloprost Drugs, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 34. Asia Pacific Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 35. China Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 36. China Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 37. China Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 38. China Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 39. Japan Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 40. Japan Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 41. Japan Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 42. Japan Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 43. India Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 44. India Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 45. India Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 46. India Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. South Korea Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 48. South Korea Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 49. South Korea Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 50. South Korea Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 51. Taiwan Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 52. Taiwan Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 53. Taiwan Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 54. Taiwan Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 55. Australia Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 56. Australia Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 57. Australia Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 58. Australia Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. Europe Iloprost Drugs, by Country USD Million (2018-2023)
  • Table 64. Europe Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 65. Europe Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 66. Europe Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 67. Europe Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 68. Germany Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 69. Germany Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 70. Germany Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 71. Germany Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 72. France Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 73. France Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 74. France Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 75. France Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 76. Italy Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 77. Italy Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 78. Italy Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 79. Italy Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 80. United Kingdom Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 81. United Kingdom Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 82. United Kingdom Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 83. United Kingdom Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 84. Netherlands Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 85. Netherlands Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 86. Netherlands Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 87. Netherlands Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 88. Rest of Europe Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 89. Rest of Europe Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 90. Rest of Europe Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 91. Rest of Europe Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. MEA Iloprost Drugs, by Country USD Million (2018-2023)
  • Table 93. MEA Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 94. MEA Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 95. MEA Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 96. MEA Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 97. Middle East Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 98. Middle East Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 99. Middle East Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 100. Middle East Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 101. Africa Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 102. Africa Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 103. Africa Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 104. Africa Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 105. North America Iloprost Drugs, by Country USD Million (2018-2023)
  • Table 106. North America Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 107. North America Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 108. North America Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 109. North America Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 110. United States Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 111. United States Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 112. United States Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 113. United States Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 114. Canada Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 115. Canada Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 116. Canada Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 117. Canada Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 118. Mexico Iloprost Drugs, by Type USD Million (2018-2023)
  • Table 119. Mexico Iloprost Drugs, by Application USD Million (2018-2023)
  • Table 120. Mexico Iloprost Drugs, by Route of Administration USD Million (2018-2023)
  • Table 121. Mexico Iloprost Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Iloprost Drugs: by Type(USD Million)
  • Table 136. Iloprost Drugs OTC , by Region USD Million (2025-2030)
  • Table 137. Iloprost Drugs Prescribed , by Region USD Million (2025-2030)
  • Table 138. Iloprost Drugs: by Application(USD Million)
  • Table 139. Iloprost Drugs Pulmonary Arterial Hypertension (PAH) , by Region USD Million (2025-2030)
  • Table 140. Iloprost Drugs High Blood Pressure , by Region USD Million (2025-2030)
  • Table 141. Iloprost Drugs: by Route of Administration(USD Million)
  • Table 142. Iloprost Drugs Intravenous , by Region USD Million (2025-2030)
  • Table 143. Iloprost Drugs Respiratory (Inhalation) , by Region USD Million (2025-2030)
  • Table 144. Iloprost Drugs: by Distribution Channel(USD Million)
  • Table 145. Iloprost Drugs Online , by Region USD Million (2025-2030)
  • Table 146. Iloprost Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 147. South America Iloprost Drugs, by Country USD Million (2025-2030)
  • Table 148. South America Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 149. South America Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 150. South America Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 151. South America Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 152. Brazil Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 153. Brazil Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 154. Brazil Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 155. Brazil Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 156. Argentina Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 157. Argentina Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 158. Argentina Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 159. Argentina Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 160. Rest of South America Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 161. Rest of South America Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 162. Rest of South America Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 163. Rest of South America Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 164. Asia Pacific Iloprost Drugs, by Country USD Million (2025-2030)
  • Table 165. Asia Pacific Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 166. Asia Pacific Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 167. Asia Pacific Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 168. Asia Pacific Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 169. China Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 170. China Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 171. China Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 172. China Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 173. Japan Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 174. Japan Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 175. Japan Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 176. Japan Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 177. India Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 178. India Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 179. India Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 180. India Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 181. South Korea Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 182. South Korea Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 183. South Korea Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 184. South Korea Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 185. Taiwan Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 186. Taiwan Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 187. Taiwan Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 188. Taiwan Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 189. Australia Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 190. Australia Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 191. Australia Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 192. Australia Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 197. Europe Iloprost Drugs, by Country USD Million (2025-2030)
  • Table 198. Europe Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 199. Europe Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 200. Europe Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 201. Europe Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 202. Germany Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 203. Germany Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 204. Germany Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 205. Germany Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 206. France Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 207. France Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 208. France Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 209. France Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 210. Italy Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 211. Italy Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 212. Italy Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 213. Italy Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 214. United Kingdom Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 215. United Kingdom Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 216. United Kingdom Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 217. United Kingdom Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 218. Netherlands Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 219. Netherlands Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 220. Netherlands Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 221. Netherlands Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 222. Rest of Europe Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 223. Rest of Europe Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 224. Rest of Europe Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 225. Rest of Europe Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 226. MEA Iloprost Drugs, by Country USD Million (2025-2030)
  • Table 227. MEA Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 228. MEA Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 229. MEA Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 230. MEA Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 231. Middle East Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 232. Middle East Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 233. Middle East Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 234. Middle East Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 235. Africa Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 236. Africa Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 237. Africa Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 238. Africa Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 239. North America Iloprost Drugs, by Country USD Million (2025-2030)
  • Table 240. North America Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 241. North America Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 242. North America Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 243. North America Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 244. United States Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 245. United States Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 246. United States Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 247. United States Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 248. Canada Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 249. Canada Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 250. Canada Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 251. Canada Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 252. Mexico Iloprost Drugs, by Type USD Million (2025-2030)
  • Table 253. Mexico Iloprost Drugs, by Application USD Million (2025-2030)
  • Table 254. Mexico Iloprost Drugs, by Route of Administration USD Million (2025-2030)
  • Table 255. Mexico Iloprost Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 256. Research Programs/Design for This Report
  • Table 257. Key Data Information from Secondary Sources
  • Table 258. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Iloprost Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Iloprost Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Iloprost Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Iloprost Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Iloprost Drugs Share (%), by Country
  • Figure 9. Asia Pacific Iloprost Drugs Share (%), by Country
  • Figure 10. Europe Iloprost Drugs Share (%), by Country
  • Figure 11. MEA Iloprost Drugs Share (%), by Country
  • Figure 12. North America Iloprost Drugs Share (%), by Country
  • Figure 13. Global Iloprost Drugs share by Players 2023 (%)
  • Figure 14. Global Iloprost Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Iloprost Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Actelion Pharmaceuticals Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Actelion Pharmaceuticals Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 21. United Therapeutics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. United Therapeutics Corporation (United States) Revenue: by Geography 2023
  • Figure 23. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc (United States) Revenue: by Geography 2023
  • Figure 25. Gilead Sciences Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Gilead Sciences Inc (United States) Revenue: by Geography 2023
  • Figure 27. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 29. Steady Med Ltd (United States) Revenue, Net Income and Gross profit
  • Figure 30. Steady Med Ltd (United States) Revenue: by Geography 2023
  • Figure 31. Teva Pharmaceuticals Inc (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceuticals Inc (Israel) Revenue: by Geography 2023
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 35. Actelion Pharmaceuticals Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Actelion Pharmaceuticals Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 37. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 39. Reata Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 40. Reata Pharmaceuticals Inc (United States) Revenue: by Geography 2023
  • Figure 41. Toray Industries Inc (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Toray Industries Inc (Japan) Revenue: by Geography 2023
  • Figure 43. Global Iloprost Drugs: by Type USD Million (2025-2030)
  • Figure 44. Global Iloprost Drugs: by Application USD Million (2025-2030)
  • Figure 45. Global Iloprost Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 46. Global Iloprost Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 47. South America Iloprost Drugs Share (%), by Country
  • Figure 48. Asia Pacific Iloprost Drugs Share (%), by Country
  • Figure 49. Europe Iloprost Drugs Share (%), by Country
  • Figure 50. MEA Iloprost Drugs Share (%), by Country
  • Figure 51. North America Iloprost Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • United Therapeutics Corporation (United States)
  • Pfizer Inc (United States)
  • Gilead Sciences Inc (United States)
  • Eli Lilly and Company (United States)
  • Steady Med Ltd (United States)
  • Teva Pharmaceuticals Inc (Israel)
  • Bayer AG (Germany)
  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Novartis International AG (Switzerland)
  • Reata Pharmaceuticals Inc (United States)
  • Toray Industries Inc (Japan)
Additional players considered in the study are as follows:
Liquidia Technologies Inc. (United States) , Nuventra Pharma Sciences (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 237 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Iloprost Drugs Quantitative research analysis
Global Iloprost Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Iloprost Drugs market are GlaxoSmithKline plc (United Kingdom), Actelion Pharmaceuticals Ltd (Switzerland), United Therapeutics Corporation (United States), Pfizer Inc (United States), Gilead Sciences Inc (United States), Eli Lilly and Company (United States), Steady Med Ltd (United States), Teva Pharmaceuticals Inc (Israel), Bayer AG (Germany), Actelion Pharmaceuticals Ltd (Switzerland), Novartis International AG (Switzerland), Reata Pharmaceuticals Inc (United States) and Toray Industries Inc (Japan).
In this highly competitive & fast evolving Iloprost Drugs industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Pulmonary Arterial Hypertension (PAH) and High Blood Pressure are the potential customers of Iloprost Drugs industry.
The Global Iloprost Drugs market is expected to see a growth of 20.3% during projected year 2023 to 2030.

Know More About Global Iloprost Drugs Report?

Have a Query? Click Here

Other Related Reports

Granisetron Comprehensive Study by Application (Chemotherapy, Radiotherapy, Nausea, Gastroparesis, Postoperative), Forms (Injection, Tablet, Syrup, Tablet, Oral Drops), Drug type (Generic drug, Paten...
$ 3350
Digital Diabetes Management Comprehensive Study by Type (Devices, Digital Diabetes Apps, Data Management Software and Platforms), Device Type (Wearable Devices, Handheld Devices), End User (Self/Home...
$ 3450
Cancer Cachexia Comprehensive Study by Type (Progestogens, Corticosteroids, Combination Therapies, Others), Application (Clinical, Screening, Research), Mechanism of Action (Appetite Stimulators, Wei...
$ 3650
Spironolactones Comprehensive Study by Application (Hospitals, Specialty Clinics, Others), Form (Liquid, Tablet), Dosage Types (Child Dosage (0-17), Adult Dosage (18-64), Senior Dosage (65 and older)...
$ 3350
Rosacea Drugs Comprehensive Study by Type (Antibiotics, Alpha agonists, Retinoids, Corticosteroids, Immunosuppressants, Antihypertensive Agents, Others), Mode of Administration (Topical, Orals), Dist...
$ 3350
Dermal Adhesives Comprehensive Study by Type (Synthetic, Natural), Application (Hospitals, Clinics), End Users (Hospitals, Clinics), Distribution Channel (Online {Company Websites, E-Commerce Website...
$ 3450